Federal Register / Vol. 88, No. 240 / Friday, December 15, 2023 / Notices 86907 

offenses he pled guilty to, including the 

offenses of: (1) importation into the 

United States a quantity of ethylone, a 

Schedule I Controlled Substance in 

violation of 21 U.S.C. 952(a) and 

960(a)(1); (2) importation into the 

United States quantities of TURINABOL 

and DIANABOL, anabolic steroids, and 

Schedule III Controlled Substances in 

violation of 21 U.S.C. 952(b) and 

960(a)(1); and (3) smuggling goods into 

the United States, that is, alpha-PVP 

ethylone, Schedule I Controlled 

Substances, and TURINBOL and 

DIANABOL, Schedule III Controlled 

Substances, in violation of 18 U.S.C. 

545. FDA’s finding that debarment is 

appropriate is based on the felony 

conviction referenced herein. The 

factual basis for this conviction is as 

follows: 

As contained in the superseding 

indictment, filed on March 22, 2018, the 

Defendant’s motion for downward 

variance, filed on April 24, 2023, and 

the Government’s sentencing 

memorandum, filed April 24, 2023, 

from Mr. Nagy’s case, Mr. Nagy was the 

owner and operator of Prescription 

Nutrition, Prescription Protein, and 

N.O.B. Industries located in 

Pennsylvania. From on or about June 

2014 to on or about September 2014, 

Mr. Nagy imported various types of 

controlled substances which he then 

capsuled and distributed to clients. 

Specifically, from on or about June 2014 

to on or about July 2014, Mr. Nagy 

illegally imported ethylone. In July 

2014, he also illegally imported 

TURINABOL and DIANABOL. In 

addition, from June 2014 until on or 

about September 2014, Mr. Nagy 

illegally imported alpha-PVP, ethylone, 

TURINABOL, and DIANABOL. All the 

controlled substances Mr. Nagy 

imported and smuggled into the country 

came from China. 

As a result of this conviction, FDA 

sent Mr. Nagy, by certified mail, on 

September 20, 2023, a notice proposing 

to debar him for a 15-year period from 

importing or offering for import any 

drug into the United States. The 

proposal was based on a finding under 

section 306(b)(3)(C) of the FD&C Act 

that Mr. Nagy’s three felony convictions 

that included: (1) importation into the 

United States a quantity of ethylone, a 

Schedule I Controlled Substance in 

violation of 21 U.S.C. 952(a) and 

960(a)(1); (2) importation into the 

United States quantities of TURINABOL 

and DIANABOL, anabolic steroids and 

Schedule III Controlled Substances in 

violation of 21 U.S.C. 952(b) and 

960(a)(1); and (3) smuggling goods into 

the United States, that is, alpha-PVP 

ethylone, Schedule I Controlled 

Substances, and TURINBOL, 

DIANABOL, Schedule III Controlled 

Substances in violation of 18 U.S.C. 545, 

were for conduct relating to the 

importation into the United States of 

any drug or controlled substance 

because he imported controlled 

substances into the United States in 

order to capsule portions of the drugs to 

sell to clients. In proposing a debarment 

period, FDA weighed the considerations 

set forth in section 306(c)(3) of the 

FD&C Act that it considered applicable 

to Mr. Nagy’s offenses and concluded 

that each offense warranted the 

imposition of a 5-year period of 

debarment, to run consecutively, for a 

total of a 15-year period of debarment. 

The proposal informed Mr. Nagy of 

the proposed debarment and offered 

him an opportunity to request a hearing, 

providing him 30 days from the date of 

receipt of the letter in which to file the 

request, and advised him that failure to 

request a hearing constituted a waiver of 

the opportunity for a hearing and of any 

contentions concerning this action. Mr. 

Nagy received the proposal and notice 

of opportunity for a hearing on 

September 22, 2023. Mr. Nagy failed to 

request a hearing within the timeframe 

prescribed by regulation and has, 

therefore, waived his opportunity for a 

hearing and waived any contentions 

concerning his debarment (21 CFR part 

12). 

II. Findings and Order 

Therefore, the Assistant 

Commissioner, Office of Human and 

Animal Food Operations, under section 

306(b)(3)(C) of the FD&C Act, under 

authority delegated to the Assistant 

Commissioner, finds that Adam Michael 

Nagy been convicted of three felonies 

under federal law for conduct relating to 

the importation into the United States of 

any drug or controlled substance. FDA 

finds that the offense should be 

accorded a debarment period of 15 years 

as provided by section 306(c)(2)(A)(iii) 

of the FD&C Act. 

As a result of the foregoing finding, 

Mr. Nagy is debarred for a period of 15 

years from importing or offering for 

import any drug into the United States, 

effective (see DATES). Pursuant to 

section 301(cc) of the FD&C Act (21 

U.S.C. 331(cc)), the importing or 

offering for import into the United 

States of any drug by, with the 

assistance of, or at the direction of Mr. 

Nagy is a prohibited act. 

Dated: December 11, 2023. 

Lauren K. Roth, 

Associate Commissioner for Policy. 

[FR Doc. 2023–27557 Filed 12–14–23; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the National Advisory 

Council on Nurse Education and 

Practice 

AGENCY: Health Resources and Services 

Administration, Department of Health 

and Human Services. 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the National 

Advisory Council on Nurse Education 

and Practice (NACNEP) will hold public 

meetings for the 2024 calendar year 

(CY). Information about NACNEP, 

agendas, and materials for these 

meetings can be found on the NACNEP 

website at https://www.hrsa.gov/ 

advisory-committees/nursing. 

DATES: NACNEP meetings will be on (all 

in Eastern Time): 

• March 14, 2024, 10 a.m.–4 p.m. and 

March 15, 2024, 10 a.m.–4 p.m.; 

• May 9, 2024, 10 a.m.–4 p.m.; 

• August 7, 2024, 10 a.m.–4 p.m. and 

August 8, 2024, 10 a.m.–4 p.m.; and 

• December 5, 2024, 8 a.m.–5 p.m. 

and December 6, 2024, 8 a.m.–2 p.m. 

ADDRESSES: Meetings may be held in 

person, via teleconference, and/or video 

conference. In-person meetings will be 

held at 5600 Fishers Lane, Rockville, 

Maryland 20857. For updates on how 

the meeting will be held and 

instructions for joining meetings, visit 

the NACNEP website at https://

www.hrsa.gov/advisory-committees/ 

nursing/meetings 14 business days 

before the date of the meeting. 

FOR FURTHER INFORMATION CONTACT: 

Justin Bala-Hampton, Designated 

Federal Official, NACNEP, Bureau of 

Health Workforce, Division of Nursing 

and Public Health, Health Resources 

and Services Administration, 5600 

Fishers Lane, 11N100D, Rockville, 

Maryland 20857; 301–443–5260; or 

Jbala-hampton@hrsa.gov. 

SUPPLEMENTARY INFORMATION: NACNEP 

provides advice and recommendations 

to the Secretary of Health and Human 

Services on policy, program 

development, and other matters of 

significance concerning the activities 

under title VIII of the Public Health 

Service Act, including the range of 

issues relating to the nurse workforce, 

education, and practice improvement. 

NACNEP also prepares and submits an 

annual report to the Secretary of Health 

and Human Services and Congress 

describing its activities, including 


ddrumheller on DSK120RN23PROD with NOTICES1
86908 Federal Register / Vol. 88, No. 240 / Friday, December 15, 2023 / Notices 

NACNEP’s findings and 

recommendations concerning activities 

under Title VIII, as required by the 

Public Health Service Act. 

Since priorities dictate meeting times, 

be advised that times and agenda items 

are subject to change. For CY 2024 

meetings, agenda items may include, 

but are not limited to, the nursing 

workforce (e.g., nursing shortage, 

distribution, supply, and access) 

nursing practice improvement, nursing 

education, nursing work environment 

and support, and other Title VIII 

program activities. Refer to the NACNEP 

website listed above for all current and 

updated information concerning the CY 

2024 NACNEP meetings. Agendas and 

meeting materials that will be posted up 

to 30 calendar days but no later 14 

calendar days before the meeting. 

Members of the public will have the 

opportunity to provide comments. 

Public participants may submit written 

statements in advance of the scheduled 

meeting(s). Oral comments will be 

honored in the order they are requested 

and may be limited as time allows. 

Requests to submit a written statement 

or make oral comments to NACNEP 

should be sent to Justin Bala-Hampton 

using the contact information above at 

least 5 business days before the meeting. 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Justin 

Bala-Hampton at the email address and 

phone number listed above at least 10 

business days before the meeting(s) they 

wish to attend. In-person meetings 

occur in a federal government building, 

and attendees must pass a security 

check to enter the building. Non-U.S. 

citizen attendees must notify Justin 

Bala-Hampton of their planned 

attendance at least 20 business days 

prior to the meeting to facilitate their 

entry into the building. All attendees are 

required to present government-issued 

identification prior to entry. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2023–27618 Filed 12–14–23; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Meeting of the Council on Graduate 

Medical Education 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, this 

notice announces that the Council on 

Graduate Medical Education (COGME or 

Council) will hold public meetings for 

the 2024 calendar year (CY). 

Information about COGME, agendas, 

and materials for these meetings can be 

found on the COGME website at https:// 

www.hrsa.gov/advisory-committees/ 

graduate-medical-edu/meetings. 

DATES: COGME meetings will be held 

on: 

• March 4, 2024, 9:00 a.m.–5:00 p.m. 

Eastern Time (ET) and March 5, 2024, 

9:00 a.m.–2:00 p.m. ET; and 

• September 12, 2024, 10:00 a.m.– 

5:00 p.m. ET and September 13, 2024, 

10:00 a.m.–3:00 p.m. ET. 

ADDRESSES: The meeting scheduled for 

March 2024 will be held in-person at 

5600 Fishers Lane, Rockville, Maryland 

20857. The meeting scheduled for 

September 2024 will be held remotely 

by teleconference/webinar. The meeting 

format is subject to change as needed. 

For any updates on how the meetings 

will be held, visit the COGME website 

30 business days before the date of the 

meeting, where instructions for joining 

meetings will be posted. For meeting 

information updates, go to the COGME 

website meeting page at https://

www.hrsa.gov/advisory-committees/ 

graduate-medical-edu/meetings. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Curi Kim, Designated Federal Official, 

Division of Medicine and Dentistry, 

Bureau of Health Workforce, HRSA, 

5600 Fishers Lane, Room 15N35, 

Rockville, Maryland 20857; 301–945– 

5827; or CKim@hrsa.gov. 

SUPPLEMENTARY INFORMATION: COGME 

provides advice and recommendations 

to the Secretary of HHS and Congress on 

policy, program development, and other 

matters of significance regarding the 

issues listed in section 762(a)(1) of the 

Public Health Service Act. Issues 

addressed by the COGME include the 

supply and distribution of the physician 

workforce in the United States, 

including any projected shortages or 

excesses; international medical 

graduates; the nature and financing of 

undergraduate and graduate medical 

education; appropriation levels for 

certain programs under Title VII of the 

Public Health Service Act; and 

deficiencies in databases concerning the 

supply and distribution of the physician 

workforce and postgraduate programs 

for training physicians. COGME submits 

reports to the Secretary of HHS; the 

Senate Committee on Health, Education, 

Labor and Pensions; and the House of 

Representatives Committee on Energy 

and Commerce. Additionally, COGME 

encourages entities providing graduate 

medical education to conduct activities 

to voluntarily achieve the 

recommendations of the Council related 

to appropriate efforts to be carried out 

by hospitals, schools of medicine, 

schools of osteopathic medicine, and 

accrediting bodies with respect to the 

supply and distribution of physicians in 

the United States; current and future 

shortages or excesses of physicians in 

medical and surgical specialties and 

subspecialties; and issues relating to 

international medical graduates, 

including efforts for changes in 

undergraduate and graduate medical 

education programs. 

Since priorities dictate meeting times, 

be advised that start times, end times, 

and agenda items are subject to change. 

For CY 2024 meetings, agenda items 

may include, but are not limited to, 

discussions on team-based care, 

graduate medical education data, and 

the topic areas listed above. Refer to the 

COGME website listed above for all 

current and updated information 

concerning the CY 2024 COGME 

meetings, including draft agendas and 

meeting materials that will be posted 30 

calendar days before the meeting. 

Members of the public will have the 

opportunity to provide comments. 

Public participants may submit written 

statements in advance of the scheduled 

meeting(s). Oral comments will be 

honored in the order they are requested 

and may be limited as time allows. 

Requests to submit a written statement 

or make oral comments to COGME 

should be sent to Dr. Kim using the 

contact information above at least 5 

business days before the meeting 

date(s). 

Individuals who need special 

assistance or another reasonable 

accommodation should notify Dr. Kim 

using the contact information listed 

above at least 10 business days before 

the meeting(s) they wish to attend. 

Since all in-person meetings occur in a 

federal government building, attendees 

must go through a security check to 

enter the building. Non-U.S. Citizen 

attendees must notify HRSA of their 

planned attendance at least 20 business 

days prior to the meeting in order to 

facilitate their entry into the building. 

All attendees are required to present 

government-issued identification prior 

to entry. 

Maria G. Button, 

Director, Executive Secretariat. 

[FR Doc. 2023–27500 Filed 12–14–23; 8:45 am] 

BILLING CODE 4165–15–P 


ddrumheller on DSK120RN23PROD with NOTICES1